AXSM offers a compelling CNS commercialization transition, with Auvelity driving growth and asymmetric upside if pipeline execution converts into profitability.
Overview
Axsome Therapeutics is a commercial-stage CNS biopharmaceutical company transitioning from development to scaled profitability through Auvelity, Sunosi and Symbravo. **Auvelity is the central asset**: Q2 2026 sales rose 51% year over year to $180.3 million, prescriptions increased 34% to approximately 266,000, and its June 2026 Alzheimer’s agitation launch produced a 126% increase in new-to-brand prescriptions among patients aged 65 and older during the first eight weeks. Symbravo adds a proprietary rapid-onset migraine platform, while Sunosi provides established sleep-disorder revenue and expansion potential. Q2 revenue was $218.4 million, but the company reported a $51.3 million net loss as SG&A reached $208.1 million to support commercialization. The stock closed at $212.74 on August 7, 2026, near the DCF value of $211.45. **The key valuation debate is execution rather than current mispricing**: the five-year probability-weighted target is $332.06, supported by a $314.29 base case, while the AXS-12 PDUFA date of May 1, 2027 provides a near-term catalyst. Risks include Symbravo’s slow ramp, payer pressure, clinical delays, variable-rate debt and continued dilution.